Relugolix combination therapy controls fibroid bleeding and lifts hemoglobin in real-world use
In 189 women with fibroids, relugolix combination therapy stopped periods in half and raised hemoglobin, but did not shrink fibroids; 37% discontinued.
Summary
Uterine fibroids often cause heavy periods and iron-deficiency anemia, which can sap energy and physical capacity for years before menopause. This real-world study followed 189 women aged 18-50 at three European hospitals who took relugolix combination therapy (relugolix, estradiol, norethisterone acetate) in routine care. About half stopped having periods, and most of the rest reported lighter bleeding. Hemoglobin rose from 10.5 to about 11.8-11.9 g/dL. Fibroid and uterine volume did not change significantly. Most women had no side effects; headache and hot flashes were the most common. Still, 37% stopped treatment, mostly because of persistent bleeding, and 47% had surgery during follow-up. The data support the drug as a bleeding-control and anemia-correcting option, including as a bridge to surgery, not as a fibroid-shrinking treatment. The summary is based on the abstract only.
Detailed Summary
Heavy menstrual bleeding from uterine fibroids is a common cause of iron-deficiency anemia in midlife women, with fatigue and reduced functional capacity as consequences. Relugolix combination therapy works by blocking GnRH receptors to suppress ovarian estrogen production, while low-dose add-back estradiol and norethisterone acetate limit menopausal-type side effects such as bone loss. Pivotal LIBERTY trials established efficacy, and this study asks how it performs in everyday practice.
Researchers conducted a multicenter, retrospective observational study from June 2023 to June 2024 at one Belgian and two Spanish hospitals. They included 189 women aged 18-50 (mean 44.4 years) with symptomatic fibroids, most commonly heavy menstrual bleeding (58.8%). Outcomes were bleeding control, amenorrhea, hemoglobin, fibroid and uterine volume, discontinuation, surgery and adverse events.
Amenorrhea was reached by 49.4% of women, on average after 64 days, and 70% of the others reported improved bleeding. Hemoglobin rose from 10.5 g/dL to 11.8 and 11.9 g/dL at follow-up points. Uterine and fibroid volume did not change significantly. Some 72.8% reported no side effects; headache (12.1%) and vasomotor symptoms (7.5%) were most frequent. However, 37.0% discontinued treatment, mainly for persistent bleeding, and 47.1% underwent surgery, only 31.5% of them after medical treatment failed.
The findings suggest the drug works on symptoms and anemia, which are surrogate and functional endpoints, rather than on tumor burden. The authors suggest counseling women about expected early breakthrough bleeding may improve adherence, and that the therapy can serve as a bridge to surgery.
Caveats: the design is retrospective and uncontrolled, so causality and comparative effectiveness cannot be established. Follow-up was about one year, so long-term bone and cardiovascular effects were not addressed. This summary relies on the abstract alone, without full methods or data.
Key Findings
- Amenorrhea occurred in 49.4% of 189 women after a mean of 64 days; 70% of the remainder reported improved bleeding.
- Hemoglobin rose from 10.5 g/dL at baseline to 11.8-11.9 g/dL, a surrogate marker of anemia correction.
- No significant change in uterine or fibroid volume: the benefit was on bleeding, not tumor shrinkage.
- 37.0% discontinued, mainly for persistent bleeding, and 47.1% had surgery during follow-up.
- 72.8% reported no side effects; headache (12.1%) and vasomotor symptoms (7.5%) were most common.
Methodology
Retrospective, multicenter observational study at three European hospitals (one Belgian, two Spanish) from June 2023 to June 2024, enrolling 189 women aged 18-50 treated in routine practice. Outcomes were bleeding, amenorrhea, hemoglobin, imaging volumes, discontinuation, surgery and adverse events. There was no control group.
Study Limitations
This summary is based on the abstract only; full methods, data and adverse-event details were not available. The retrospective, uncontrolled design, high discontinuation and surgery rates, and roughly one-year follow-up limit conclusions on comparative efficacy and long-term safety such as bone density.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
